VALNEVA (EPA:VLA) | WebDisclosure

PRESS RELEASE

published on 04/18/2025 at 10:00, 11 months 5 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring

Valneva CDC Chikungunya Vaccine IXCHIQ® ACIP Recommendation
PRESS RELEASE

published on 04/18/2025 at 10:00, 11 months 5 days ago

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya

Valneva Vaccin Chikungunya IXCHIQ® ACIP
BRIEF

published on 04/09/2025 at 07:05, 11 months 14 days ago

Vaccination du premier enfant dans l'étude de Phase 2 sur le vaccin S4V2 contre la shigellose

Valneva Phase 2 Shigellose Vaccin S4V2 Essai Pédiatrique
BRIEF

published on 04/09/2025 at 07:05, 11 months 14 days ago

First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva Phase 2 Shigellosis S4V2 Vaccine Pediatric Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 14 days ago

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva Vaccin Shigellose LimmaTech Étude Pédiatrique
PRESS RELEASE

published on 04/09/2025 at 07:00, 11 months 14 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 03/20/2025 at 07:00, 1 year ago

Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières
PRESS RELEASE

published on 03/20/2025 at 07:00, 1 year ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Valneva SE reports solid full year 2024 results exceeding growth targets. Financial outlook for 2025 includes strong revenue growth and strategic investments. Key milestones and financial information discussed

Financial Results Valneva 2025 Outlook Vaccine Company Clinical Progress
BRIEF

published on 02/05/2025 at 07:05, 1 year 1 month ago

Valneva Achieves UK Approval for World's First Chikungunya Vaccine

Public Health Valneva Chikungunya Vaccine UK Approval Travel Safety
BRIEF

published on 02/05/2025 at 07:05, 1 year 1 month ago

Valneva obtient l'approbation du Royaume-Uni pour le premier vaccin contre le chikungunya au monde

Valneva Santé Publique Vaccin Contre Le Chikungunya Approbation Du Royaume-Uni Sécurité En Voyage

Published on 03/23/2026 at 08:00, 2 hours 16 minutes ago

ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
Published on 03/23/2026 at 02:00, 8 hours 16 minutes ago

FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 23:00, 2 days 11 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 2 days 12 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 2 days 13 hours ago

Earthwise Minerals Announces Private Placement

View all ACCESSWIRE

Published on 03/23/2026 at 09:19, 57 minutes ago

Mister Spex Chooses Salesforce to further develop its Omnichannel Strategy
Published on 03/23/2026 at 09:00, 1 hour 16 minutes ago

Removal: Tower Bridge Funding 2022-1 PLC
Published on 03/23/2026 at 09:00, 1 hour 16 minutes ago

Removal: Imara Gold plc
Published on 03/23/2026 at 09:00, 1 hour 16 minutes ago

Official List Notice
Published on 03/23/2026 at 09:00, 1 hour 16 minutes ago

EQS Group launches Risk Management module to support continuous data and AI risk oversight

View all EQS

Published on 03/23/2026 at 08:10, 2 hours 6 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 15 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 15 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 16 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 16 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE

News